Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Fresenius Medical Care ( (FMS) ) has issued an update.
Fresenius Medical Care announced its return to the DAX 40 Index, effective December 27, 2024, marking a significant achievement for the company as it represents the top tier of publicly traded companies in Germany. The CEO, Helen Giza, emphasized that this milestone reflects the company’s successful performance turnaround and strategic execution, reinforcing its commitment to innovation and growth. The inclusion in the DAX 40 not only highlights Fresenius Medical Care’s substantial market presence but also underscores the dedication of its workforce to enhancing shareholder and patient value.
More about Fresenius Medical Care
Fresenius Medical Care is the world’s leading provider of products and services for individuals with renal diseases. The company operates a network of 3,732 dialysis clinics, providing treatment for approximately 308,000 patients globally. Additionally, it is a leading supplier of dialysis products such as dialysis machines and dialyzers. Fresenius Medical Care is publicly traded on the Frankfurt Stock Exchange and the New York Stock Exchange.
YTD Price Performance: 10.09%
Average Trading Volume: 269,386
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $13.35B
For detailed information about FMS stock, go to TipRanks’ Stock Analysis page.
